Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate

Executive Summary

Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.


Related Content

Molteni Farmaceutici Plans For EU Entry Of Titan’s Six-Month Buprenorphine Implant
Daiichi Denies OTC Business Sale But Would It Make Sense?
Santhera Shores Up Finances With Chiesi Deal for Raxone
Lured By Its Discovery Platform And Pipeline, Amgen Bids For Nuevolution
Google's Verily Makes Clinical Trials Pitch With Big Pharma Pacts
Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio
Sandoz Strikes Shionogi Partnership as Part of Pain Play
New EU Approvals
Viela Adds Momentum To Burgeoning NMOSD Market With Pivotal Inebilizumab Results
J&J's Yondelis Leads New Wave Of Sarcoma Drugs


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts